Investigation of transcatheter arterial chemoembolization for Unresectable primary liver cancer
10.3760/cma.j.issn.1008-6315.2015.10.006
- VernacularTitle:肝动脉化疗栓塞术治疗不能手术切除原发性肝癌的临床分析
- Author:
Beizhan NIU
;
Shuang SI
;
Shuguang CHEN
- Publication Type:Journal Article
- Keywords:
Primary liver cancer;
Transcatheter arterial chemoembolization;
Individual treatment;
Comprehensive treatment
- From:
Clinical Medicine of China
2015;31(10):884-886
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the therapeutic measures of unresectable primary liver cancer (PLC) with transcatheter arterial chemoembolization(TACE).Methods The clinical data,treatment measures and followed up data of 312 patients with unresectable primary liver cancer from January 1991 to March 2010 were analyzed retrospectively.Of these 312 patients, different dosages, measures of transcatheter arterial chemoembolization together with immunotherapy and nutritional support treatments were given to the patients according to their own statements, including the patency of portal vein (evaluated by portography), the range, blood supply and lipiodol concentration of the lesions (evaluated by hepatic arteriography), and the systemic conditions.Some of these patients also accepted cryotherapy, radio frequency ablation (RFA), percutaneous ethanol injection therapy.Results Two hundred and eighty-seven patients were followed up (92％).Forty-two cases accepted the two-stage operation as the lesions were localized or reduced.In these 42 patients, 34 cases accepted the hepatectomy, 8 cases accepted the cryotherapy.The 1,3 and 5 year survival rate of all patients were 87.6％, 33.1％ and 13.2％.Conclusion TACE for unresectable primary liver cancer should be used individually and comprehensivly.Surgical treatment should be taken once the lesions can be resected.
